Gisteren hebben KiKa en Oncode Institute een overeenkomst getekend om de komende jaren intensief samen te werken op het gebied van kinderkankeronderzoek.

Oncode Institute accelerates the path from fundamental discovery to patient impact by supporting clinical proof of concept projects that turn scientific insights into diagnostics and therapies.

MRM Health has entered into a strategic research collaboration with Oncode Institute and the Netherlands Cancer Institute (NKI) to accelerate the development of microbiome-based therapies that enhance the effectiveness of cancer immunotherapy. 

Researchers have discovered a way to extend the effectiveness of hormone therapy using a safe, inexpensive, and widely used class of drugs: corticosteroids. The new findings, published in Nature, pave the way for a clinical study starting in 2026.

It started with an unexpected e-mail. An US biotech company working on immunotherapies had picked up a strange signal: an protein appeared to bind to LAIR-1, a receptor that dampens immune cells. But why this was happening remained unclear. 

In a lab at the Netherlands’ UMC Utrecht, researcher Madelon Maurice was chasing a fundamental question: could the cell’s own machinery be harnessed to degrade, rather than merely inhibit, disease-causing proteins on the cell surface? What at first was basic science soon revealed itself as a radical new path in drug discovery.

The new research programme SPARC has been awarded a prestigious NWO Perspectief grant. This national funding supports large collaborations between researchers and industry to create innovations with real impact on society.

Every year, hundreds of participants cycle up Alpe d’Huez to raise funds for cancer research. 
For Oncode Institute, Alpe d'HuZes is more than a challenge — it’s a symbol of community, perseverance, and purpose.

As the year draws to a close, the Oncode community once again gathered at the iconic Royal Tropical Institute in Amsterdam for two days of science, inspiration, and connection.

During the Dutch Life Sciences Conference, Myriagon was announced as the winner of the Venture Challenge Fall 2025.

Researchers have discovered a potent group of T cells that physically cling to tumour cells. The study, led by Oncode Investigator Daniel Peeper and published in Nature, opens a new direction for improving immunotherapy.

Oncode Researchers develop a faster, more flexible way to find new medicines - no DNA tags required.

After 30 years of mystery, scientists reveal how BRCA2-deficient tumors evade chemotherapy, and how we might stop them.

From DNA to RNA to proteins, the event highlighted cutting-edge methods redefining how scientists map, measure, and model the central dogma.

Are you passionate about the latest digital marketing trends and looking to take your career to the next level? Join our dynamic team at Oncode Institute!

What happens when a gene guards its own power source? Researchers discovered that Sox2 keeps its enhancer in check, revealing new rules of genome organization.